165 related articles for article (PubMed ID: 34472116)
1. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
[TBL] [Abstract][Full Text] [Related]
2. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
3. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
[TBL] [Abstract][Full Text] [Related]
4. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
[TBL] [Abstract][Full Text] [Related]
5. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab.
Ye Z; Wolf LA; Mettman D; Plapp FV
Vox Sang; 2020 Feb; 115(2):207-212. PubMed ID: 31729042
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
[TBL] [Abstract][Full Text] [Related]
7. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
[TBL] [Abstract][Full Text] [Related]
8. Extending shelf life of dithiothreitol-treated panel RBCs to 28 days.
Sigle JP; Mihm B; Suna R; Bargetzi M
Vox Sang; 2018 May; 113(4):397-399. PubMed ID: 29512161
[TBL] [Abstract][Full Text] [Related]
9. Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing.
Tremblay T; Branch DR; Loubaki L
Transfusion; 2020 Sep; 60(9):2090-2096. PubMed ID: 32632934
[TBL] [Abstract][Full Text] [Related]
10. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
11. Antibody incidence and red blood cell transfusions in patients on daratumumab.
Tauscher C; Moldenhauer S; Bryant S; DiGuardo M; Jacob EK
Transfusion; 2021 Dec; 61(12):3468-3472. PubMed ID: 34617617
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
[TBL] [Abstract][Full Text] [Related]
13. The impact of Daratumumab on transfusion service costs.
Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
[TBL] [Abstract][Full Text] [Related]
14. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
[TBL] [Abstract][Full Text] [Related]
16. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
[TBL] [Abstract][Full Text] [Related]
17. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals.
Youssef M; Arnesen C; Arledge C; Langley C; Sylvester D; Sikora J; Marques MB; Long Zheng X; Williams LA
Transfus Apher Sci; 2019 Apr; 58(2):152-155. PubMed ID: 30639177
[TBL] [Abstract][Full Text] [Related]
18. The Challenges of Daratumumab in Transfusion Medicine.
Dizon MF
Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
[TBL] [Abstract][Full Text] [Related]
19. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
20. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab.
Disbro WL
Immunohematology; 2017 Sep; 33(3):105-109. PubMed ID: 29043827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
